Age-Related Macular Degeneration

As novel treatment options, including biosimilars, for age-related macular degeneration emerge, it has become a “fascinating time to practice,” according to Aleksandra Rachitskaya, MD.

NEW YORK — Andrew A. Moshfeghi, MD, MBA, discusses upcoming changes in the management of age-related macular degeneration in his presentation at OSN New York Retina.

Sanofi will invest up to $60 million in Gyroscope Therapeutics, with the proceeds funding the ongoing clinical trials of GT005 for geographic atrophy secondary to age-related macular degeneration, according to a press release.

Genentech announced the FDA has approved ranibizumab 100 mg/mL injection for wet age-related macular degeneration in patients who previously responded to at least two anti-VEGF injections.

Apellis Pharmaceuticals reported topline results from two phase 3 studies investigating pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration, according to a press release.

In his keynote Euretina Lecture, delivered at the virtual Euretina congress, SriniVas Sadda, MD, highlighted the critical role of the choriocapillaris in age-related macular degeneration.

Results from a pilot study showed the effectiveness of LumiThera’s Valeda Light Delivery System in patients with dry age-related macular degeneration.

Visus Therapeutics has entered into worldwide exclusive licensing agreements with Cella Therapeutics and DelSiTech, according to a press release.

There are a couple of different considerations when putting an advanced technology lens in a patient who has at least signs of macular degeneration vs. more advanced changes in the retina.

Age-related macular degeneration is the leading cause of vision loss in people older than 60 years in the United States, affecting an estimated 11 million to 15 million individuals.